AI Article Synopsis
- The subcutaneous implantable cardioverter defibrillator (S-ICD) offers a safe and effective alternative for preventing sudden cardiac death compared to the traditional trans-venous ICD (TV-ICD).
- Recent studies show that S-ICD patients now include those with serious heart issues and other health problems, expanding beyond just younger patients with channelopathies.
- The review assesses the evidence supporting S-ICD use and points out discrepancies between existing guidelines and how it's actually used in clinical settings.
Article Abstract
The subcutaneous implantable cardioverter defibrillator (S-ICD) is a valuable alternative to the conventional trans-venous ICD (TV-ICD) for the prevention of sudden cardiac death (SCD). Prospective registries showed that the S-ICD is safe and effective in treating ventricular tachyarrhythmias in high-risk patients without pacing indications. While in earlier studies patients implanted with S-ICDs were young and mostly affected by channelopathies, contemporary S-ICD cohorts include patients with severely impaired left ventricular function and significant comorbidities. This review focuses on S-ICD evidence-based use and highlights current gaps between guidelines recommendations and real-world clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2019.04.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!